Adam Crystal - Nov 1, 2023 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
President, Research & Development
Signature
/s/ Douglas Barry, attorney-in-fact
Stock symbol
TNGX
Transactions as of
Nov 1, 2023
Transactions value $
-$62,994
Form type
4
Date filed
11/2/2023, 04:49 PM
Previous filing
Mar 2, 2023
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Sale -$63K -7.51K -8.46% $8.39 81.3K Nov 1, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,507 shares that were acquired on October 31, 2023 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

President, Research & Development